Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus TAYTULLA.
ENSKYCE vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One capsule orally once daily for 24 weeks.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive